Improved Sleep Continuity and Increased Slow Wave Sleep and REM Latency During Ziprasidone Treatment: A Randomized, Controlled, Crossover Trial of 12 Healthy Male Subjects
J Clin Psychiatry 2005;66(8):989-996
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: Ziprasidone, an atypical
antipsychotic, is a potent dopamine (D2) and serotonin
(5-HT2A/C) receptor blocker, has agonistic properties
at the 5-HT1A receptor, and blocks serotonin and
norepinephrine reuptake. These transmitter systems are closely
related to the regulation of sleep.
Method: The aim of this double-blind,
placebo-controlled, randomized, crossover study was to
investigate the effects of ziprasidone on polysomnographic sleep
structure and subjective sleep quality. Twelve healthy male
subjects were randomly assigned to receive ziprasidone 40 mg or
placebo for 2 sessions each composed of 2 consecutive nights
(night 1, standard sleep conditions; night 2, acoustic stress) 5
days apart. Treatment was administered orally 2 hours before
bedtime. The study was conducted from April 2004 to July 2004.
Results: Ziprasidone significantly increased
total sleep time, sleep efficiency, percentage of sleep stage 2,
and slow wave sleep; decreased the number of awakenings; and
significantly affected tonic and phasic REM sleep parameters,
i.e., it decreased percentage of REM and REM density and
profoundly increased REM latency.
Conclusion: Ziprasidone's effects on the sleep
profile are somehow opposite to what is known about sleep of
depressed patients (e.g., disturbances of sleep continuity, a
reduciton of slow wave sleep, and a disinhibition of REM sleep).
Its REM sleep-suppressing properties resemble those of most,
although not all, antidepressants and may be clinically relevant.
The drug also demonstrates sleep-consolidating properties under
both standard routine and acoustic stress conditions. These
effects are most likely related to ziprasidone's 5-HT2C antagonism, 5-HT1A agonism, and serotonin and
norepinephrine reuptake inhibition.